Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 49, Issue 1 (Jan 2011)

Issues

Non-invasive assessment of liver fibrosis: it is time for laboratory medicine

Giada Sebastiani
  • Department of Digestive Diseases, Hepatology and Clinical Nutrition, Dell'Angelo Hospital, Venice, Venetian Institute of Molecular Medicine (VIMM), Padova, Italy
/ Konstantinos Gkouvatsos
  • Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Canada
/ Mario Plebani
  • Department of Laboratory Medicine, University-Hospital of Padova, and Leonardo Foundation, Abano Terme General Hospital, Padova, Italy
  • Email:
Published Online: 2010-10-20 | DOI: https://doi.org/10.1515/CCLM.2011.001

Abstract

Chronic liver diseases (CLDs) represent a major cause of morbidity and mortality worldwide. In all etiologies of CLDs, staging of liver fibrosis is essential for both prognosis and management. Until a few years ago, liver biopsy was the only tool for the diagnosis of liver fibrosis in patients with CLDs. However, liver biopsy is an invasive and costly procedure. More recently, various serum biomarkers and laboratory tests have been proposed as surrogates of liver histology. Due to inadequate diagnostic accuracy or to lack of sufficient validation, guidelines still do not recommend them as a substitute for liver biopsy that is still considered the gold standard for the diagnosis of liver fibrosis. Notably, non-invasive serum biomarkers, when combined, may reduce by 50%–80% the number of liver biopsies needed for correctly classifying hepatic fibrosis. However, liver biopsy cannot be avoided completely, but should be used in those cases in which non-invasive methods show poor accuracy. In this view, serum biomarkers and liver biopsy represent a union between laboratory medicine and hepatology.

Keywords: combination algorithms; diagnostic performance; liver biopsy; liver fibrosis; non-invasive biomarkers; staging

About the article

Corresponding author: Mario Plebani, Department of Laboratory Medicine, University-Hospital, Via Giustiniani, 2, 35128 Padova, Italy Phone: +39 049 8212792, Fax: +39 049 663240


Received: 2010-03-10

Accepted: 2010-05-25

Published Online: 2010-10-20

Published in Print: 2011-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.001. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Xiaoning Wang, Guoxiang Xie, Xiaoyan Wang, Mingmei Zhou, Huan Yu, Yan Lin, Guangli Du, Guoan Luo, and Ping Liu
Evidence-Based Complementary and Alternative Medicine, 2015, Volume 2015, Page 1
[2]
Peter Hauff, Ulrich Gottwald, and Matthias Ocker
Expert Opinion on Investigational Drugs, 2015, Volume 24, Number 3, Page 309
[3]
Sven Radcke, John F. Dillon, and Aja L. Murray
European Journal of Gastroenterology & Hepatology, 2015, Volume 27, Number 1, Page 1
[4]
Woo Kyoung Jeong, Hyo K. Lim, Hyoung-Ki Lee, Jae Moon Jo, and Yongsoo Kim
Ultrasonography, 2014, Volume 33, Number 3, Page 149
[5]
P. P. Basu, M. M. Aloysius, N. J. Shah, and R. S. Brown Jr
Alimentary Pharmacology & Therapeutics, 2014, Volume 39, Number 8, Page 790
[6]
Thierry Poynard, Gilles Lenaour, Jean Christophe Vaillant, Frederique Capron, Mona Munteanu, Daniel Eyraud, Yen Ngo, Helmi M'Kada, Vlad Ratziu, Laurent Hannoun, and Frederic Charlotte
Clinical Gastroenterology and Hepatology, 2012, Volume 10, Number 6, Page 657
[7]
E.G.M. Lazarova, M.Y.V. Fernandez, M. Adler, and B. Gulbis
Immuno-analyse & Biologie Spécialisée, 2011, Volume 26, Number 5-6, Page 217
[8]
Jordi Tor and Roberto Muga
Medicina Clínica, 2011, Volume 137, Number 14, Page 642

Comments (0)

Please log in or register to comment.
Log in